Packaging of drugs will be more informative
This article was translated by an automatic translation system, and was therefore not reviewed by people.
The packaging of drugs will be more informative. A proposal to include both Anvisa, for example, drugs with sedative effect, a symbol of warning, accompanied by the words "no go". The packages should also provide information in Braille (name of the active, concentration, pharmaceutical form and SAC) to ensure accessibility to the product.
These and other changes suggested by the Public Consultation No 08/2009 to receive contributions on May 11. The purpose of CP is that labeling allows the identification of appropriate drug for their dispensing and use, and east on the proper storage of products, as well as the safe use of medicine, with the provision of information and warnings which are necessary for rational use.
"The proposal was made to solve problems that have been identified in the market and claimed by both the population as by associations of the sector," says the director-president of Anvisa, Dirceu Raposo de Mello. "The goal is to make information on the packaging of the product clear and useful to the citizen," he emphasizes.
The document also proposes that information already found in the leaflets are also placed on packages, such as substances in medicine and changes in the care of conservation after opening the product. "These changes are important to people who are allergic to any component of the formula know this before you open the package," said Raposo.
Contributions may be sent by the virtual forum for discussion or through a form provided. The form (word) should be sent to email @ cp.rotulagem anvisa.gov.br, fax: (61) 3462-5428 or by mail to: National Health Surveillance Agency, General Management of Medicines - Sector of Industry and Supply (CIS), Trecho 05, Special Area 57, Brasília - DF, CEP: 71205-050.
Information: Ascom / Press office of Anvisa
Source: Anvisa
This article was translated by an automatic translation system, and was therefore not reviewed by people.
Important:
The JurisWay site does not interfere in the work provided by doctrine, why only reflect the opinions, ideas and concepts of their authors.
